WSJ
24 Jul 2026, 06:32 UTC · 2h ago
Sanofi to Drop Eczema Drug Amid Review of Pipeline Under New CEO
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Search tags
WSJ
24 Jul 2026, 06:32 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Search tags
What the story claims
1 claim · each scored for market impact
The drugmaker is halting the development of amlitelimab for atopic dermatitis due to insufficient efficacy and safety data. — The termination of a drug candidate represents a loss of potential future revenue and wasted R&D investment.
-0.80Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Continue reading
6 related stories
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
WSJ
22h ago
